[64Cu]Cu-SAR-bisFAP

[64Cu]Cu-SAR-bisFAP is a targeted copper-64 (64Cu) radiopharmaceutical diagnostic agent developed by Clarity Pharmaceuticals for PET imaging of various solid tumors. It utilizes a dimeric (bis) targeting ligand based on the FAP inhibitor UAMC1110, which is conjugated to a proprietary sarcophagine (SAR) chelator. This dimeric structure is designed to enhance binding affinity and tumor retention compared to monomeric FAP-targeting agents. The drug specifically targets Fibroblast Activation Protein (FAP), a protein highly expressed on cancer-associated fibroblasts (CAFs) within the tumor microenvironment but minimally present in healthy tissues. As part of a Targeted Copper Theranostic (TCT) approach, [64Cu]Cu-SAR-bisFAP serves as the imaging companion to the therapeutic isotope version, [67Cu]Cu-SAR-bisFAP, enabling a see-and-treat strategy for pan-cancer applications.

Other names

64Cu-SAR-bisFAP